Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

REporting recommendations for tumor MARKer prognostic studies (REMARK).

Lisa M McShane1, Douglas G Altman, Willi Sauerbrei

  • 1National Cancer Institute, Biometric Research Branch, DCTD, Room 8126, Executive Plaza North, MSC 7434, 6130 Executive Boulevard, Bethesda, MD 20892-7434, USA. Lm5h@nih.gov

Nature Clinical Practice. Oncology
|September 1, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population attributable fraction.

BMJ (Clinical research ed.)·2018
Same author

Reporting guidelines for oncology research: helping to maximise the impact of your research.

British journal of cancer·2018
Same author

Updating standards for reporting diagnostic accuracy: the development of STARD 2015.

Research integrity and peer review·2018
Same author

Do declarative titles affect readers' perceptions of research findings? A randomized trial.

Research integrity and peer review·2018
Same author

Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries.

PloS one·2018
Same author

The INTERGROWTH-21<sup>st</sup> fetal growth standards: toward the global integration of pregnancy and pediatric care.

American journal of obstetrics and gynecology·2018

Clinical utility of tumor markers in oncology is limited due to inconsistent study results. New reporting guidelines are proposed to improve the transparency and rigor of tumor marker studies.

Area of Science:

  • Oncology
  • Biomarker Research
  • Clinical Diagnostics

Background:

  • Tumor marker research has yielded few clinically useful markers despite extensive investigation.
  • Inconsistent conclusions across studies hinder the reliable application of tumor markers in cancer diagnostics.
  • Methodological issues and incomplete reporting in published studies contribute to discrepancies.

Framework:

  • Development of reporting guidelines for tumor marker studies, inspired by CONSORT and STARD initiatives.
  • Guidelines aim to standardize the reporting of study design, hypotheses, patient and specimen characteristics, assay methods, and statistical analyses.
  • Emphasis on transparent and complete reporting to enable critical appraisal of study quality and generalizability.

Implementation:

Related Experiment Videos

  • Guidelines address essential information needed for assessing tumor marker study validity.
  • Suggestions provided for data presentation and discussion elements within publications.
  • Focus on enhancing the reproducibility and interpretability of tumor marker research findings.

    • Implications:

    • Improved reporting will facilitate better judgment of tumor marker data usefulness and applicability.
    • Aims to increase the number of reliable and clinically actionable tumor markers for cancer management.
    • Contributes to advancing the field of cancer diagnostics through enhanced research transparency.